Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LITT and Early Temozolomide for Recurrent Glioblastoma
NCT05663125Phase 2Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of temozolomide in glioblastoma (GBM), sponsored by Beijing Tiantan Hospital. Status: unknown.
02
Drugs
temozolomide
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05663125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05663125.